Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
513 rows where has_known_aptamer = 0, surface_class = "A_surface" and tier = "Tier 1.5" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: pdb_count_total
tier 1
- Tier 1.5 · 513 ✖
surface_class 1
- A_surface · 513 ✖
has_known_aptamer 1
- - · 513 ✖
has_activation_state_pdb_pair 1
- 0 513
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P36021 | SLC16A2 | Monocarboxylate transporter 8 | Tier 1.5 | 0.956 | 1 | A_surface | 7 | 79.56 | 1 | 0 | 0 | 0 | 1 | Allan-Herndon-Dudley syndrome | 0.8533069932022032 | |||
| P51795 | CLCN5 | H(+)/Cl(-) exchange transporter 5 | Tier 1.5 | 0.955 | 1 | A_surface | 2 | 80.62 | 0 | 0 | 0 | 0 | 1 | Dent disease type 1 | 0.850724240157394 | |||
| Q14524 | SCN5A | Sodium channel protein type 5 subunit alpha | Tier 1.5 | 0.953 | 1 | A_surface | 16 | 67.25 | 1 | 0 | 0 | 0 | 1 | long QT syndrome 3 | 0.8448298602976083 | |||
| Q969N2 | PIGT | GPI-anchor transamidase component PIGT | Tier 1.5 | 0.953 | 1 | A_surface | 3 | 87.25 | 1 | 0 | 0 | 0 | 1 | multiple congenital anomalies-hypotonia-seizures syndrome 3 | 0.8439030764005646 | |||
| P13637 | ATP1A3 | Sodium/potassium-transporting ATPase subunit alpha-3 | Tier 1.5 | 0.953 | 1 | A_surface | 5 | 88.81 | 1 | 0 | 0 | 0 | 1 | alternating hemiplegia of childhood 2 | 0.842328126568451 | |||
| Q99250 | SCN2A | Sodium channel protein type 2 subunit alpha | Tier 1.5 | 0.952 | 1 | A_surface | 5 | 68.81 | 1 | 0 | 0 | 0 | 1 | developmental and epileptic encephalopathy, 11 | 0.8388748085806758 | |||
| P25189 | MPZ | Myelin protein P0 | Tier 1.5 | 0.951 | 1 | A_surface | 2 | 81.69 | 0 | 0 | 0 | 0 | 1 | Charcot-Marie-Tooth disease type 1B | 0.8377022197539885 | |||
| Q9HAB3 | SLC52A2 | Solute carrier family 52, riboflavin transporter, member 2 | Tier 1.5 | 0.95 | 1 | A_surface | 1 | 84.12 | 1 | 0 | 0 | 0 | 1 | riboflavin transporter deficiency | 0.8333271825486935 | |||
| Q9Y653 | ADGRG1 | Adhesion G-protein coupled receptor G1 | Tier 1.5 | 0.95 | 1 | A_surface | 1 | 77.88 | 1 | 0 | 0 | 0 | 1 | bilateral frontoparietal polymicrogyria | 0.8322298896713178 | |||
| P13473 | LAMP2 | Lysosome-associated membrane glycoprotein 2 | Tier 1.5 | 0.948 | 1 | A_surface | 2 | 83.19 | 0 | 0 | 0 | 0 | 1 | Glycogen Storage Disease Type 2b | 0.8273010649608126 | |||
| P14770 | GP9 | Platelet glycoprotein IX | Tier 1.5 | 0.947 | 1 | A_surface | 2 | 84.69 | 1 | 0 | 0 | 0 | 1 | Bernard-Soulier syndrome | 0.8233582238860002 | |||
| P51798 | CLCN7 | H(+)/Cl(-) exchange transporter 7 | Tier 1.5 | 0.942 | 1 | A_surface | 9 | 80.94 | 1 | 0 | 0 | 0 | 1 | Autosomal recessive malignant osteopetrosis | 0.8065499095904218 | |||
| Q96JI7 | SPG11 | Spatacsin | Tier 1.5 | 0.937 | 1 | A_surface | 3 | 66.75 | 1 | 0 | 0 | 0 | 1 | Autosomal recessive spastic paraplegia type 11 | 0.7886006646085494 | |||
| Q8TD43 | TRPM4 | Transient receptor potential cation channel subfamily M member 4 | Tier 1.5 | 0.936 | 1 | A_surface | 25 | 77.44 | 1 | 0 | 0 | 0 | 1 | Familial progressive cardiac conduction defect | 0.7868180621357534 | |||
| P05023 | ATP1A1 | Sodium/potassium-transporting ATPase subunit alpha-1 | Tier 1.5 | 0.936 | 1 | A_surface | 10 | 88.69 | 1 | 0 | 0 | 0 | 1 | Charcot-Marie-tooth disease, axonal, type 2DD | 0.7868851290226483 | |||
| O94856 | NFASC | Neurofascin | Tier 1.5 | 0.933 | 1 | A_surface | 2 | 76.31 | 0 | 0 | 0 | 0 | 1 | neurodevelopmental disorder with central and peripheral motor dysfunction | 0.7782432580663833 | |||
| Q15746 | MYLK | Myosin light chain kinase, smooth muscle | Tier 1.5 | 0.93 | 1 | A_surface | 7 | 65.88 | 0 | 0 | 0 | 0 | 1 | aortic aneurysm, familial thoracic 7 | 0.7659842793171938 | |||
| Q02094 | RHAG | Ammonium transporter Rh type A | Tier 1.5 | 0.929 | 1 | A_surface | 8 | 95.62 | 1 | 0 | 0 | 0 | 1 | Rh deficiency syndrome | 0.764209214915708 | |||
| P00846 | MT-ATP6 | ATP synthase F(0) complex subunit a | Tier 1.5 | 0.928 | 1 | A_surface | 10 | 88.94 | 1 | 0 | 0 | 0 | 1 | NARP syndrome | 0.760749518172638 | |||
| Q02413 | DSG1 | Desmoglein-1 | Tier 1.5 | 0.92 | 1 | A_surface | 1 | 62.06 | 0 | 0 | 0 | 0 | 1 | severe dermatitis-multiple allergies-metabolic wasting syndrome | 0.7335328506238418 | |||
| O15554 | KCNN4 | Intermediate conductance calcium-activated potassium channel protein 4 | Tier 1.5 | 0.914 | 1 | A_surface | 17 | 84.19 | 1 | 0 | 0 | 0 | 1 | dehydrated hereditary stomatocytosis | 0.7145864899974032 | |||
| O75110 | ATP9A | Probable phospholipid-transporting ATPase IIA | Tier 1.5 | 0.914 | 1 | A_surface | 4 | 84.19 | 1 | 0 | 0 | 0 | 1 | neurodevelopmental disorder with poor growth and behavioral abnormalities | 0.7120328673255018 | |||
| Q9NR82 | KCNQ5 | Potassium voltage-gated channel subfamily KQT member 5 | Tier 1.5 | 0.913 | 1 | A_surface | 5 | 56.41 | 1 | 0 | 0 | 0 | 1 | intellectual disability, autosomal dominant 46 | 0.7086662845211597 | |||
| P51797 | CLCN6 | H(+)/Cl(-) exchange transporter 6 | Tier 1.5 | 0.897 | 1 | A_surface | 3 | 77.81 | 1 | 0 | 0 | 0 | 1 | neurodegeneration, childhood-onset, with hypotonia, respiratory insufficiency, and brain imaging abnormalities | 0.6554030932062199 | |||
| P21731 | TBXA2R | Thromboxane A2 receptor | Tier 1.5 | 0.892 | 1 | A_surface | 6 | 86.25 | 1 | 0 | 0 | 0 | 1 | bleeding diathesis due to thromboxane synthesis deficiency | 0.639967145559869 | |||
| Q13555 | CAMK2G | Calcium/calmodulin-dependent protein kinase type II subunit gamma | Tier 1.5 | 0.891 | 1 | A_surface | 2 | 78.38 | 0 | 0 | 0 | 0 | 1 | intellectual developmental disorder 59 | 0.6354497016986491 | |||
| P54709 | ATP1B3 | Sodium/potassium-transporting ATPase subunit beta-3 | Tier 1.5 | 0.88 | 1 | A_surface | 7 | 89.69 | 1 | 0 | 0 | 0 | 1 | congestive heart failure | 0.5999952111132625 | |||
| Q92956 | TNFRSF14 | Tumor necrosis factor receptor superfamily member 14 | Tier 1.5 | 0.879 | 1 | A_surface | 8 | 79.94 | 0 | 0 | 0 | 0 | 1 | diffuse large B-cell lymphoma | 0.5983171413833771 | |||
| P01597 | IGKV1-39 | Immunoglobulin kappa variable 1-39 | Tier 1.5 | 0.876 | 1 | A_surface | 2 | 90.5 | 0 | 0 | 0 | 0 | 1 | cutaneous Leishmaniasis | 0.5868213846274001 | |||
| P01764 | IGHV3-23 | Immunoglobulin heavy variable 3-23 | Tier 1.5 | 0.876 | 1 | A_surface | 6 | 91.0 | 0 | 0 | 0 | 0 | 1 | cutaneous Leishmaniasis | 0.5868213846274001 | |||
| P01825 | IGHV4-59 | Immunoglobulin heavy variable 4-59 | Tier 1.5 | 0.876 | 1 | A_surface | 3 | 91.56 | 1 | 0 | 0 | 0 | 1 | cutaneous Leishmaniasis | 0.5868213846274001 | |||
| P23083 | IGHV1-2 | Immunoglobulin heavy variable 1-2 | Tier 1.5 | 0.876 | 1 | A_surface | 1 | 91.75 | 0 | 0 | 0 | 0 | 1 | cutaneous Leishmaniasis | 0.5868213846274001 | |||
| P01593 | IGKV1D-33 | Immunoglobulin kappa variable 1D-33 | Tier 1.5 | 0.876 | 1 | A_surface | 6 | 90.88 | 0 | 0 | 0 | 0 | 1 | cutaneous Leishmaniasis | 0.5868213846274001 | |||
| P06312 | IGKV4-1 | Immunoglobulin kappa variable 4-1 | Tier 1.5 | 0.876 | 1 | A_surface | 10 | 90.62 | 0 | 0 | 0 | 0 | 1 | cutaneous Leishmaniasis | 0.5868213846274001 | |||
| P15954 | COX7C | Cytochrome c oxidase subunit 7C, mitochondrial | Tier 1.5 | 0.868 | 1 | A_surface | 3 | 91.38 | 1 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.5589133210585959 | |||
| P41440 | SLC19A1 | Reduced folate transporter | Tier 1.5 | 0.866 | 1 | A_surface | 19 | 72.06 | 1 | 0 | 0 | 0 | 1 | Knobloch syndrome | 0.5526223217595396 | |||
| Q96D96 | HVCN1 | Voltage-gated hydrogen channel 1 | Tier 1.5 | 0.865 | 1 | A_surface | 2 | 69.75 | 0 | 0 | 0 | 0 | 1 | Joubert syndrome | 0.5504227269701596 | |||
| Q9P1W8 | SIRPG | Signal-regulatory protein gamma | Tier 1.5 | 0.864 | 1 | A_surface | 2 | 85.5 | 0 | 0 | 0 | 0 | 1 | type 1 diabetes mellitus | 0.5457344827318543 | |||
| O15155 | BET1 | BET1 homolog | Tier 1.5 | 0.864 | 1 | A_surface | 1 | 83.06 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.5468418315282804 | |||
| P34741 | SDC2 | Syndecan-2 | Tier 1.5 | 0.863 | 1 | A_surface | 1 | 60.84 | 0 | 0 | 0 | 0 | 1 | COVID-19 | 0.5422254875204983 | |||
| Q8TEM1 | NUP210 | Nuclear pore membrane glycoprotein 210 | Tier 1.5 | 0.862 | 1 | A_surface | 2 | 79.56 | 1 | 0 | 0 | 0 | 1 | HIV infection | 0.5409211817593593 | |||
| O00161 | SNAP23 | Synaptosomal-associated protein 23 | Tier 1.5 | 0.859 | 1 | A_surface | 2 | 82.12 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.5288361677964304 | |||
| P54756 | EPHA5 | Ephrin type-A receptor 5 | Tier 1.5 | 0.858 | 1 | A_surface | 2 | 79.38 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.5261379875719714 | |||
| Q9HCM2 | PLXNA4 | Plexin-A4 | Tier 1.5 | 0.856 | 1 | A_surface | 1 | 83.06 | 0 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.518371001420808 | |||
| Q9Y6M7 | SLC4A7 | Sodium bicarbonate cotransporter 3 | Tier 1.5 | 0.856 | 1 | A_surface | 1 | 67.5 | 1 | 0 | 0 | 0 | 1 | hypertension | 0.5199335074832467 | |||
| P15814 | IGLL1 | Immunoglobulin lambda-like polypeptide 1 | Tier 1.5 | 0.85 | 1 | A_surface | 3 | 75.06 | 0 | 0 | 0 | 0 | 1 | isolated agammaglobulinemia | 0.4996673834185043 | |||
| P18084 | ITGB5 | Integrin beta-5 | Tier 1.5 | 0.846 | 1 | A_surface | 3 | 82.19 | 0 | 0 | 0 | 0 | 1 | migraine disorder | 0.48652455084344876 | |||
| Q92536 | SLC7A6 | Y+L amino acid transporter 2 | Tier 1.5 | 0.846 | 1 | A_surface | 2 | 83.19 | 1 | 0 | 0 | 0 | 1 | Abnormality of the skeletal system | 0.48544421359843914 | |||
| P14616 | INSRR | Insulin receptor-related protein | Tier 1.5 | 0.838 | 1 | A_surface | 4 | 78.0 | 1 | 0 | 0 | 0 | 1 | neurodegenerative disease | 0.4589515676875687 | |||
| A1L3X0 | ELOVL7 | Very long chain fatty acid elongase 7 | Tier 1.5 | 0.828 | 1 | A_surface | 1 | 89.75 | 0 | 0 | 0 | 0 | 1 | substance-related disorder | 0.4271436896798171 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;